{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:07:25Z","timestamp":1772165245959,"version":"3.50.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,28]]},"abstract":"<jats:p>In 2008, we reported favorable 5-year outcomes of nonmyeloablative allogeneic stem cell transplantation after fludarabine, cyclophosphamide, rituximab (FCR) conditioning for relapsed and chemosensitive follicular lymphoma. However, innovative strategies were still needed to treat patients with chemorefractory disease. We therefore subsequently performed a trial in which 90Y-ibritumomab tiuxetan (0.4 mCi\/kg) was added to the fludarabine, cyclophosphamide conditioning regimen (90YFC). Here, we report updated results of the FCR trial and outcomes after 90YFC. For the FCR group (N = 47), since the last update, one patient developed recurrent disease. With a median follow-up of 107 months (range, 72-142 months), the 11-year overall survival and progression-free survival rates were 78%, and 72%, respectively. For the 90YFC group (N = 26), more patients had chemorefractory disease than did those in the FCR group (38% and 0%, P &lt; .001). With a median follow-up of 33 months (range,17-94 months), the 3-year progression-free survival rates for patients with chemorefractory and chemosensitive disease were 80% and 87%, respectively (P = .7). The low frequency of relapse observed after a long follow-up interval of 9 years in the FCR group suggests that these patients are cured of their disease. The addition of 90Y to the conditioning regimen appears to be effective in patients with chemorefractory disease. This trial was registered at www.clinicaltrials.gov as NCT00048737.<\/jats:p>","DOI":"10.1182\/blood-2012-03-417808","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T01:56:03Z","timestamp":1337046963000},"page":"6373-6378","source":"Crossref","is-referenced-by-count":87,"title":["Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results"],"prefix":"10.1182","volume":"119","author":[{"given":"Issa F.","family":"Khouri","sequence":"first","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima M.","family":"Saliba","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Erwin","sequence":"additional","affiliation":[{"name":"Imaging Physics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry I.","family":"Samuels","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Korbling","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Hematopathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamar","family":"Valverde","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin M.","family":"Alousi","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Anderlini","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Gulbis","sequence":"additional","affiliation":[{"name":"Pharmacy Clinical Programs,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday R.","family":"Popat","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Lymphoma and Myeloma, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Lymphoma and Myeloma, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Lymphoma and Myeloma, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homer A.","family":"Macapinlac","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"17","key":"2019102204522102100_B1","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019102204522102100_B2","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumumab-tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of phase 1\/2 study.","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2019102204522102100_B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019102204522102100_B4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"issue":"12","key":"2019102204522102100_B5","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019102204522102100_B6","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritimumab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed non-Hodgkin's lymphoma.","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019102204522102100_B7","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma: NCI Sponsored International Working Group.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019102204522102100_B8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019102204522102100_B9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centers of PET reporting criteria designed for use in multicenter trials in Hodgkin's lymphoma.","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2019102204522102100_B10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma.","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019102204522102100_B11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.exphem.2003.09.021","article-title":"Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.","volume":"32","author":"Khouri","year":"2004","journal-title":"Exp Hematol"},{"issue":"6","key":"2019102204522102100_B12","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019102204522102100_B13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: 1. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"282","key":"2019102204522102100_B14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"21","key":"2019102204522102100_B15","first-page":"3397","volume":"23","author":"Kalbfleish","year":"1980","journal-title":"The Statistical Analysis of Failure Time Data"},{"issue":"10","key":"2019102204522102100_B16","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","article-title":"Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.","volume":"23","author":"Khouri","year":"2005","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019102204522102100_B17","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"2019102204522102100_B18","first-page":"486a","article-title":"Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (pts) with advanced idolent NHL and CLL: CALGB 109901 [abstract].","volume":"110","author":"Shea","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"2019102204522102100_B19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019102204522102100_B20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced-intensity conditioning HLA-identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.","volume":"95","author":"Pi\u00f1ana","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"2019102204522102100_B21","first-page":"874a","article-title":"Mature results of BEAM\/high-dose rituximab vs BEAM\/yttrium-90 ibritumomab tiuxetan (Zevalin) and autologous stem cell transplantation (ASCT) for relapsed CD20+ follicular and diffuse large b-cell lymphoma: survival outcomes and risk of secondary malignancies [abstract].","volume":"118","author":"Zipp","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"2019102204522102100_B22","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019102204522102100_B23","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"90Y-ibritumumab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/26\/6373\/1497579\/zh802612006373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/26\/6373\/1497579\/zh802612006373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T05:00:40Z","timestamp":1571720440000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/26\/6373\/105580\/Nonmyeloablative-allogeneic-transplantation-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,28]]},"references-count":23,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2012,6,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-417808","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717297955.792752808","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,28]]}}}